Biosimilars: PBAC ‘a’ flags infliximab

inflectra story, checkered race winning flag
The PBAC today recommended that Inflectra (infliximab), the first monoclonal antibody ‘mAb’ biosimilar registered in Australia, be added to the Pharmaceutical Benefits Scheme. The recommendation is the first step towards unlocking greater savings for Australia’s health system which currently spends more than $100 million annually on a comparable therapy, says Hospira. Inflectra will be used

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Long working hours linked to higher risk of stroke
Next $5 million in grants to Australian research on type 2 diabetes